Obese Patients with Sleep Apnea Syndrome Treated by Progesterone

16Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Two obese patients with sleep apnea syndrome were administered chlormadinone acetate (CMA), a synthetic progesterone, known as a potent respiratory stimulant to augment load compensation response as well as CO2 chemosensitivity. Before CMA administration, both cases showed normal chemosensitivity of hypoxic and hypercapnic ventilatory responses (HVR and HCVR) at daytime, although marked oxygen desaturation with sleep apnea was observed. During CMA administration for 7 days, HVR, HCVR and occlusion pressure response to flow-resistive loading were altogether augmented. In one case obstructive sleep apnea (OSA) was altered to obstructive hypopnea, and in the other case central apnea disappeared completely, resulting in remarkable improvement of oxygen desaturation at sleep and daytime somnolence in both cases. We conclude that CMA might be useful in the treatment of sleep apnea syndrome. © 1988, Tohoku University Medical Press. All rights reserved.

Cite

CITATION STYLE

APA

Kimura, H., Tatsumi, K., Kunitomo, F., Okita, S., Tojima, H., Kouchiyama, S., … Kuriyama, T. (1988). Obese Patients with Sleep Apnea Syndrome Treated by Progesterone. Tohoku Journal of Experimental Medicine, 156, 151–157. https://doi.org/10.1620/tjem.156.Suppl_151

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free